ImmuPharma

Executive Summary

ImmuPharma is a UK-based biotechnology company pioneering a new generation of precision therapies for autoimmune diseases. Leveraging its proprietary peptide-based platform, the company aims to address the root causes of autoimmune conditions, offering potentially disease-modifying treatments. Additionally, ImmuPharma is developing a prodrug of glucagon for use in artificial pancreas systems, targeting diabetes management. Founded in 2025, the company is in early preclinical stages with no disclosed funding or valuation. Its focus on root-cause-oriented therapies positions it in a high-value niche, but the lack of clinical data and financial transparency adds significant risk. The company operates in a competitive landscape with established autoimmune players, yet its novel approach could differentiate it if successfully validated.

Upcoming Catalysts (preview)

• TBDPreclinical data release for lead autoimmune candidate20% success
• TBDPartnership or licensing deal for glucagon prodrug15% success
• TBDInitiation of IND-enabling studies25% success